Edwards Lifesciences (EW) Free Cash Flow (2009 - 2026)

Edwards Lifesciences has reported Free Cash Flow for 18 years, with the latest figure at $585.0 million in Q2 2026.

• On a quarterly basis, Free Cash Flow rose 142.84% year-over-year to $585.0 million in Q2 2026; TTM through Jun 2026 was $1.4 billion, a 143.85% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 360.5% from the prior year.
• Free Cash Flow was $585.0 million for Q2 2026 at Edwards Lifesciences, up from -$21.1 million in the prior quarter.
• The five-year high for Free Cash Flow was $585.0 million in Q2 2026, with the low at -$177.3 million in Q4 2024.
• Average Free Cash Flow over 5 years is $211.4 million, with a median of $245.4 million recorded in 2022.
• The largest YoY upside for Free Cash Flow was 2100.7% in 2024 against a maximum downside of 467.08% in 2024.
• Over 5 years, Free Cash Flow stood at $213.9 million in 2022, then plunged by 77.42% to $48.3 million in 2023, then slumped by 467.08% to -$177.3 million in 2024, then surged by 299.38% to $353.5 million in 2025, then jumped by 65.49% to $585.0 million in 2026.
• The last three Free Cash Flow figures came in at $585.0 million (Q2 2026), -$21.1 million (Q1 2026), and $353.5 million (Q4 2025), per Business Quant data.